You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Havrix Junior Long-term protection

Havrix Junior: up to 50 years of predicted long-term immunity*1,2

Two doses of Havrix Junior are predicted to provide long-term protection of at least up to 50 years following childhood administration1,2

Hepatitis A and its shifting endemicity

The importance of prevention and vaccination

Vaccination is one of the best ways to help prevent hepatitis A infection5,6

Hepatitis A vaccines

The impact of universal Vaccination

The impact of universal vaccination against hepatitis A

Universal vaccination programmes in countries with intermediate endemicity can help protect individuals from hepatitis A infection and disease and reduce virus circulation8

See the impact

*A descriptive analysis was used to predict long-term seropositivity results for children based on studies of vaccines containing inactivated hepatitis A antigen either as standalone hepatitis A vaccine or combination hepatitis A and B vaccine. In order to extrapolate outcomes in children using data in adults, studies with data on adult vaccine doses of hepatitis A and B vaccine 720 EU or hepatitis A vaccine 1,440 EU were selected2


  1. Havrix Junior SmPC, January 2022.
  2. Agrawal A et al. Infect Dis Ther 2020; 9:785–796.
  3. World Health Organization (WHO). WHO immunological basis for immunization series. Module 18: Hepatitis A. Available at: (Accessed April 2023). 
  4. World Health Organization (WHO). Hepatitis A key facts. Available at: (Accessed April 2023).
  5. World Health Organization. Wkly Epidemiol Rec 2022; 97:493–512.
  6. Centers for Disease Control and Prevention (CDC). Hepatitis A questions and answers for the public. Available at: (Accessed April 2023).
  7. Van Der Meeren O et al. Hum Vaccin Immunother 2015; 11:1729–1734.
  8. Stuurman AL et al. Hum Vaccin Immunother 2017; 13:724–736.

For more information, please refer to the prescribing information or contact GlaxoSmithKline
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
To report quality complaint/s associated with the use of GSK product/s, please contact us via

GlaxoSmithKline Biologicals SA. Rixensart, Belgium
© 2023 GSK group of companies or its licensor
Trademark is owned by or licensed to the GSK group of companies

PM-RCH-HAV-WCNT-230002 | Date of preparation: Noember 2023